Rationale and Design of the Mechanistic Potential of Antihypertensives in Preclinical Alzheimer’s (HEART) Trial
- 19 December 2017
- journal article
- research article
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 61 (2) , 815-824
Abstract
Research indicates that certain antihypertensive medications alter Alzheimer’s disease (AD) biomarkers in Caucasians. The renin angiotensin system (RAS) regulates blood pressure (BP) in the body and the brain and may directly influence AD biomarkers,Keywords
This publication has 49 references indexed in Scilit:
- Current status of renin–aldosterone angiotensin system-targeting anti-hypertensive drugs as therapeutic options for Alzheimer's diseaseExpert Opinion on Investigational Drugs, 2013
- Impact of Angiotensin Receptor Blockers on Alzheimer Disease Neuropathology in a Large Brain Autopsy SeriesArchives of Neurology, 2012
- Comparative efficacy and safety of combination aliskiren/amlodipine and amlodipine monotherapy in African Americans with stage 2 hypertension and obesity or metabolic syndromeJournal of the American Society of Hypertension, 2011
- Know Thyself: Real-World Behavioral Correlates of Self-Appraisal AccuracyThe Clinical Neuropsychologist, 2011
- Distinct neuroanatomical substrates and cognitive mechanisms of figure copy performance in Alzheimer's disease and behavioral variant frontotemporal dementiaNeuropsychologia, 2011
- Conflict monitoring in early frontotemporal dementiaNeurology, 2009
- Angiotensin-Converting Enzyme Inhibitors and Cognitive Decline in Older Adults With HypertensionArchives of internal medicine (1960), 2009
- Validity and Calibration of Food Frequency Questionnaires Used with African-American Adults in the Jackson Heart StudyJournal of the American Dietetic Association, 2009
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984
- The CES-D ScaleApplied Psychological Measurement, 1977